HER2-positive cancers
Apr 15, 2024
ENHERTU: Another Triumph to Celebrate for AstraZeneca and Daiichi Sankyo
ENHERTU lies at the core of AstraZeneca and Daiichi Sankyo’s objectives for advancing in oncology. This collaboration has notably broadened the antibody-drug conjugates impact in the United States. On April 5, 2024, the FDA approved ENHERTU to treat HER2-positive solid tumors in adults who have received previous sy...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
